Graves Ophthalmopathy Score
Loading...
References
- Wilmar M Wiersinga. Thyroid eye disease (Graves' orbitopathy): clinical presentation, epidemiology, pathogenesis, and management.. The lancet. Diabetes & endocrinology, 2025
- Yang Li. Multidimensional predictive model for assessing clinical activity in thyroid eye disease.. Frontiers in medicine, 2025
- Aimin Sun. The Efficacy and Safety of Intravenous Tocilizumab to Treat Graves' Ophthalmopathy: A Systematic Review and Single-arm Meta-analysis.. The Journal of clinical endocrinology and metabolism, 2025
- Yanlin Xu. Comprehensive Comparisons of Different Treatments for Active Graves Orbitopathy: A Systematic Review and Bayesian Model-Based Network Meta-Analysis.. The Journal of clinical endocrinology and metabolism, 2025
- Kenneth Ka Hei Lai. Low clinical activity score, 'progressive' thyroid eye disease: presentations of 1439 patients from a tertiary centre in Hong Kong.. The British journal of ophthalmology, 2025
- P. Perros. INTER-OBSERVER VARIABILITY OF CLINICAL ACTIVITY SCORE ASSESSMENTS IN PATIENTS WITH THYROID EYE DISEASE.. American journal of ophthalmology, 2023
- L Bartalena. The 2021 European Group on Graves' orbitopathy (EUGOGO) clinical practice guidelines for the medical management of Graves' orbitopathy.. European journal of endocrinology, 2021
- Raymond S. Douglas. Teprotumumab for the Treatment of Active Thyroid Eye Disease.. The New England journal of medicine, 2020
- G. Kahaly. Mycophenolate plus methylprednisolone versus methylprednisolone alone in active, moderate-to-severe Graves' orbitopathy (MINGO): a randomised, observer-masked, multicentre trial.. The lancet. Diabetes & endocrinology, 2018
- Terry J. Smith. Teprotumumab for Thyroid‐Associated Ophthalmopathy. The New England Journal of Medicine, 2017